⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory small lymphocytic lymphoma

Every month we try and update this database with for refractory small lymphocytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01886859
Recurrent B-Cel...
Recurrent Chron...
Recurrent Small...
Refractory B-Ce...
Refractory Chro...
Refractory Smal...
Ibrutinib
Lenalidomide
18 Years - National Cancer Institute (NCI)
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00290004
Chronic Lymphoc...
Small Lymphocyt...
Leukemia
Lymphoma
motexafin gadol...
18 Years - Pharmacyclics LLC.
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589
Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaNCT01008462
B-Cell Prolymph...
Hypodiploidy
Loss of Chromos...
Plasma Cell Leu...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Plasm...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Non-...
Refractory Plas...
Refractory Smal...
t(14;16)
t(4;14)
T-Cell Prolymph...
Waldenstrom Mac...
Allogeneic Bone...
Allogeneic Hema...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Peripheral Bloo...
Tacrolimus
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
NK Cells in Cord Blood TransplantationNCT01619761
Accelerated Pha...
Acute Biphenoty...
Acute Lymphobla...
Acute Myeloid L...
Chronic Phase C...
DS Stage II Pla...
DS Stage III Pl...
High Grade B-Ce...
ISS Stage II Pl...
ISS Stage III P...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Small...
Refractory Acut...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
Secondary Acute...
Therapy-Related...
Therapy-Related...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Lenalidomide
Melphalan
Mycophenolate M...
Natural Killer ...
Rituximab
Tacrolimus
Total-Body Irra...
Umbilical Cord ...
- 75 YearsM.D. Anderson Cancer Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasNCT02332980
Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaNCT03010358
Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589
Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT02225275
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Lenalidomide
Obinutuzumab
18 Years - M.D. Anderson Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaNCT02568553
Recurrent Burki...
Recurrent Diffu...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Gray-...
Recurrent Mantl...
Recurrent Margi...
Recurrent Media...
Recurrent Non-H...
Recurrent Small...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Gray...
Refractory Mant...
Refractory Marg...
Refractory Medi...
Refractory Non-...
Refractory Smal...
Blinatumomab
Lenalidomide
18 Years - National Cancer Institute (NCI)
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00100711
Chronic Lymphoc...
Small Lymphocyt...
Motexafin Gadol...
18 Years - Pharmacyclics LLC.
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT04169737
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Acalabrutinib
Obinutuzumab
Venetoclax
18 Years - M.D. Anderson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaNCT00005803
Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLNCT03045328
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Ibrutinib
Venetoclax
18 Years - Stanford University
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT03961672
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Duvelisib
18 Years - City of Hope Medical Center
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaNCT01995669
Grade 3a Follic...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Laboratory Biom...
Lenalidomide
Obinutuzumab
18 Years - M.D. Anderson Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01886859
Recurrent B-Cel...
Recurrent Chron...
Recurrent Small...
Refractory B-Ce...
Refractory Chro...
Refractory Smal...
Ibrutinib
Lenalidomide
18 Years - National Cancer Institute (NCI)
CD19-Specific T Cells Post AlloSCTNCT03579888
B Acute Lymphob...
Recurrent B Acu...
Recurrent Chron...
Recurrent Diffu...
Recurrent Mantl...
Recurrent Non-H...
Recurrent Ph-Li...
Recurrent Prima...
Recurrent Small...
Refractory B Ac...
Refractory Chro...
Refractory Diff...
Refractory Mant...
Refractory Non-...
Refractory Ph-L...
Refractory Prim...
Refractory Smal...
Autologous CD19...
Cyclophosphamid...
Fludarabine
18 Years - 70 YearsM.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryNCT02160015
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Electrocardiogr...
Ibrutinib
Lenalidomide
Magnetic Resona...
Rituximab
18 Years - National Cancer Institute (NCI)
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationNCT02420912
Loss of Chromos...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Nivolumab
18 Years - M.D. Anderson Cancer Center
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerNCT00789776
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Diffuse Large B...
Previously Trea...
Recurrent Chron...
Recurrent Chron...
Recurrent Indol...
Recurrent Mantl...
Recurrent Plasm...
Recurrent Small...
Refractory Chro...
Refractory Hodg...
Refractory Plas...
Refractory Smal...
Waldenstrom Mac...
Allogeneic Bone...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Natural Killer ...
Tacrolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaNCT00005803
Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT03961672
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Duvelisib
18 Years - City of Hope Medical Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasNCT02332980
Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaNCT03010358
Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00290004
Chronic Lymphoc...
Small Lymphocyt...
Leukemia
Lymphoma
motexafin gadol...
18 Years - Pharmacyclics LLC.
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaNCT02756897
Chronic Lymphoc...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Small Lymphocyt...
Ibrutinib
Laboratory Biom...
Venetoclax
18 Years - M.D. Anderson Cancer Center
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaNCT04578600
Indolent B-Cell...
Recurrent B-Cel...
Recurrent Chron...
Recurrent Mucos...
Recurrent Folli...
Recurrent Hairy...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Chro...
Refractory Muco...
Refractory Foll...
Refractory Hair...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Recurrent Small...
Refractory Smal...
Lenalidomide
Obinutuzumab
Oral Azacitidin...
18 Years - University of California, Davis
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLNCT03045328
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Ibrutinib
Venetoclax
18 Years - Stanford University
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: